Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Daniel J. Haraf and Louis Portugal.
|
|
Connection Strength |
|
 |
|
 |
|
0.565 |
|
|
|
-
Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.159
-
Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.068
-
Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.064
-
Gooi Z, Richmon J, Agrawal N, Blair E, Portugal L, Vokes E, Seiwert T, de Souza J, Saloura V, Haraf D, Goldenberg D, Chan J. AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 02; 39(2):201-205.
Score: 0.042
-
Stenson KM, Maccracken E, Kunnavakkam R, W Cohen EE, Portugal LD, Villaflor V, Seiwert T, Blair E, Haraf DJ, Salama JK, Vokes EE. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7.
Score: 0.030
-
Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
Score: 0.029
-
Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.029
-
Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.028
-
Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
Score: 0.026
-
Villaflor VM, Cohen EE, Haraf D, Stenson K, Blair E, Salama J, Portugal L, Williams R, Thomas A, Gomez-Abuin G, Vokes EE. Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):6030.
Score: 0.023
-
Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L, Weichselbaum RW, Vokes EE. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86.
Score: 0.018
-
Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
Score: 0.018
-
Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.016
-
Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|